Drug Discovery World

APRIL 10, 2023

Beckley Psytech has initiated a Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD). Beckley Psytech’s Phase IIa study, taking place at King’s College Hospital in London, will explore the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with AUD.

Pharmacokinetics 130

Pharmacokinetics FDA Approval Hospitals Treatment 130

Drug Discovery World

AUGUST 9, 2024

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. The dose expansion portion of the study will evaluate treatment at the recommended Phase II dose in multiple indications.

Trials 147

Trials Pharmacokinetics Drugs Clinical Trials 147

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. We hope that this EP4-targeting approach will deliver a promising route to improving treatment options for patients with a broad range of cancers.”

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

OCTOBER 30, 2023

Kura Oncology’s FIT-001 Phase I dose-escalation trial of KO-2806, a farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumours, has commenced with the dosing of the first patient.

Trials 130

Trials Pharmacokinetics Therapies Treatment 130

Drug Discovery World

NOVEMBER 10, 2023

Dense aggregates of immune cells, including CD8 positive granzyme B positive cytotoxic T cells, dendritic cells, and B cells, were observed in PDAC tissue after CAN-2409 treatment, confirming activation of a robust antitumoral immune response.

Pharmacokinetics 130

Pharmacokinetics Clinical Trials Immune Response Treatment 130

Drug Discovery World

MARCH 15, 2024

The Phase Ib study examined the safety, tolerability and pharmacokinetics of twice-daily oral doses of ALX-001 in 32 heathy adult participants aged 50-80. The findings were presented at the AD/PD 2024 Conference in Lisbon. Study results show that ALX-001 was safe in cognitively normal older adults at all tested doses. “The

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Many cell lines used in pancreatic cancer research, for example, are generally not genetically aligned with most patients in the clinic.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. Armed with this understanding, the researchers further demonstrated that the genetic inhibition of DGAT1 suppresses radioresistance.

FDA Approval 130

FDA Approval FDA Drugs Pharmacokinetics 130

Drug Discovery World

AUGUST 13, 2024

Animal models (AMs) have generally been seen as useful for drug development and biomedical research for many years. They are assumed to closely mimic human disease progression and act as a good testing ground for toxicology studies and pharmacokinetics 1. Are AMs always necessary and unavoidable? Possibly not.

Drug Development 162

Drug Development Animal Testing Regulations Drugs 162

Drug Discovery World

FEBRUARY 2, 2024

The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201. The findings were published in the New England Journal of Medicine.

Pharmacokinetics 130

Pharmacokinetics Drugs International Clinical Trials 130

Drug Discovery World

SEPTEMBER 1, 2022

These sequence-defined, recombinant antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for evolocumab and its biosimilars. Evolocumab is a monoclonal antibody used for the treatment of hyperlipidemia, or elevated levels of cholesterol and other lipoproteins.

Drug Development 130

Drug Development Biosimilars Pharmacokinetics Drugs 130

Drug Discovery World

APRIL 5, 2023

The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, London. It targets a pathway that cancer cells are highly dependent upon, involving the heat shock factor 1 protein (HSF1). It also supports the drug’s potential to treat other cancers.

Clinical Trials 130

Clinical Trials Pharmacokinetics Drugs DNA 130

Alta Sciences

SEPTEMBER 13, 2023

Four Pain Models Altasciences Uses to Assess Treatments During Clinical Trials pmjackson Wed, 09/13/2023 - 17:01 September is pain awareness month, and the importance of pain management and continued research into effective analgesics is integral to helping patients suffering from various pain conditions.

Clinical Trials 52

Clinical Trials Treatment Trials Drug Development 52

Drug Discovery World

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. . The trial recently advanced to the fourth dose cohort of patients at 200mg/m2, following a positive review of the safety and tolerability data from the third cohort.

FDA 130

FDA Pharmacokinetics Drugs Clinical Trials 130

Drug Discovery World

JUNE 27, 2023

The Commonwealth Government’s Medical Research Future Fund (MRFF) has invested $9.75 He said: “Creating molecules for medicines from promising research ‘hits’ is a huge challenge and remains a major gap in Australian drug discovery efforts. MedChem Australia will fill this gap.

Drugs 130

Drugs Medical Chemistry Pharmacokinetics Science 130

Drug Discovery World

OCTOBER 25, 2023

The second, dose-expansion, phase of the study (Phase Ib) is to further evaluate the safety, pharmacokinetics / pharmacodynamics, and efficacy of IKS014 at the recommended Phase II dose. We hope that this trial of IKS014 could lead to improved treatment options for patients with HER2+ solid tumours.”

Pharmacokinetics 130

Pharmacokinetics Trials Drugs Clinical Trials 130

Drug Discovery World

JUNE 27, 2023

Young Kwon, Chief Executive Officer of Alchemab, said: “Alchemab’s unique approach to antibody research has led to the discovery of ATLX-1088, which we hope could be a new therapy for Alzheimer’s. This could lead to a potent drug with fewer side effects.

Pharmacokinetics 130

Pharmacokinetics Therapies Disease Treatment 130

Drug Discovery World

JUNE 29, 2023

To mark the occasion, this article summarises the most recent news about the ways drug discovery is improving wellbeing and mental health through innovative new treatments and therapies. EVX-101 is a sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin, and low-dose carbidopa.

Drugs 130

Drugs Pharmacokinetics Trials FDA 130

Drug Discovery World

JULY 25, 2023

The pharmaceutical industry is constantly developing evidence-based treatments for children while there continue to be scientific advancements related to new modalities and disease understanding. About the authors Justin Hay is a Senior Director at Certara with more than 20 years of clinical pharmacology experience.

Drug Development 130

Drug Development Clinical Pharmacology Pharmacokinetics Drugs 130

Drug Discovery World

APRIL 3, 2024

A public-private consortium formed by the biotech Hemostatics, based at the Barcelona Science Park, the Clínica Universidad de Navarra (CUN) and the Institute of Chemical Research of Catalonia (ICIQ), has received €2.5 The post Validating a revolutionary therapy against lethal haemorrhage appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Laboratories Pharmacokinetics Treatment 130

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. In January 2023, QN-302 received Orphan Drug Designation by the FDA for the potential treatment of pancreatic cancer. This deadly cancer has a 5-year survival rate of just 7%.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Regulations 130

Drug Discovery World

JANUARY 9, 2023

When the cancer metastases, which it does in approximately 50% of patients, there are limited treatment options and projected overall survival is only a year. . Part A of the study investigated the safety and pharmacokinetics of continuous daily dosing of IOA-244 at 10, 20, 40 and 80mg. .

FDA 130

FDA Drugs Pharmacokinetics Trials 130

Drug Discovery World

DECEMBER 14, 2023

Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including hormone receptor-positive (HR+) and triple negative breast cancers. months of additional follow-up and 78.3% The results show a 25.1%

Therapies 130

Therapies Trials Pharmacokinetics Treatment 130

The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. A focus of the presentation will be on the target engagement results and pharmacokinetics from its ongoing monotherapy dose-escalation study to explore a potential optimal dose and schedule to effectively inhibit AhR.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. In January 2023, QN-302 received Orphan Drug Designation by the FDA for the potential treatment of pancreatic cancer. This deadly cancer has a 5-year survival rate of just 7%.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

Drug Discovery World

MAY 31, 2023

In the Phase I/II trial, three of the four tumour evaluable patients had a best response of stable disease, and two patients continue treatment as of the data cut-off date. This allows Teff and NK cells to expand and kill tumour cells.

Pharmacokinetics 130

Pharmacokinetics Trials Clinical Trials Treatment 130

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. 4] , [5] , [6].

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

MARCH 9, 2021

Because maturation inhibitors use a unique mechanism of action that targets HIV differently than other antiretrovirals currently available, they have the potential to offer new treatment options for individuals who may have experienced resistance to other classes of HIV treatment. Kimberly Smith, M.D., Kimberly Smith, M.D.,

Treatment 52

Treatment RNA Pharmacokinetics Virus 52

DrugBank

MARCH 7, 2024

Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options.

Pharmaceutical Companies 82

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 82

Drug Discovery World

AUGUST 3, 2023

For example, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition to date 1. With this in mind, the FDA claims to be committed to sound scientific research into the area and has a number of processes in place for those in the medical research community who intend to study cannabis 1.

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

Drug Discovery World

NOVEMBER 20, 2023

Personalised cancer vaccines require a particularly fast turnaround time to allow the unique profile of the patient’s cancer to be reflected in the treatment and avoid delays in initiating treatment as the disease progresses.

DNA 173

DNA Engineering Vaccine Therapies 173

Conversations in Drug Development Trends

AUGUST 9, 2024

It broadens recruitment strategies, diversifies the patient population, and expands the study population, thus increasing access to potentially life-saving treatments. These trials increase the chances of success by enabling the early detection of effective treatments in defined populations and focusing efforts on the most promising options.

Trials 80

Trials Clinical Trials Regulations FDA 80

The Pharma Data

APRIL 16, 2021

for the treatment of COVID-19 – as planned with the FDA – follows the modification of contracts with the U.S. Lilly’s chief scientific officer and president of Lilly Research Laboratories. variant, present in these other countries and remain an important treatment option. This request is not due to any new safety concern.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

Drug Target Review

MARCH 6, 2024

Based on preclinical data, we expect broad opportunities in haematology and oncology for LSD1 inhibitors, pointing towards potential efficacy in SCLC and AML in combination with standard of care treatments. This results in the induction of leukaemic blast cell differentiation which can slow or stop the expansion of tumour cells.

Production 64

Production Pharmacokinetics Pharmacy RNA 64

Drug Discovery World

SEPTEMBER 26, 2022

Perhaps the biggest benefit drug repurposing brings is its potential to get treatments to patients faster than traditional means of drug discovery. This type of digital archiving intends to make data readily available and easily accessible for companies pursuing pharmaceutical research and development. . Benefits and barriers .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Target Review

JUNE 12, 2023

Leveraging AI-guided structure-based drug design, Insilico’s research and development team generated an impressive portfolio of over 6,000 molecules and identified three highly promising hit series. What is the potential therapeutic target of ISM6331 in the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92